Columbus, OH – According to filings with the U.S. Securities and Exchange Commission, Sollis Therapeutics is raising $2,500,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Alex Dinello played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Sollis Therapeutics

Sollis Therapeutics is a clinical-stage specialty pharmaceutical company developing novel non-steroid, non-opioid analgesics. Sollis’ first product is an extended release combination analgesic and anti-inflammatory drug designed for local delivery for the treatment of sciatica and other neuropathic pain syndromes. Sollis was founded and received seed-funding from an Ohio-based organization, the Neurotechnology Innovations Translator (NIT). Sollis also received a grant from the Ohio Opioid Abuse, Prevention and Treatment Technology Initiative.

To learn more about Sollis Therapeutics, visit http://www.sollistx.com/

Contact:
Alex Dinello, President and Chief Executive Officer
614-636-4971
https://www.linkedin.com/in/alex-dinello-65042a8/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved